PMID- 35280794
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220620
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - The Value of Serum Tumor Markers and Blood Inflammation Markers in 
      Differentiating Pancreatic Serous Cystic Neoplasms and Pancreatic Mucinous Cystic 
      Neoplasms.
PG  - 831355
LID - 10.3389/fonc.2022.831355 [doi]
LID - 831355
AB  - Although many studies have emphasized the prognostic and diagnostic value of 
      tumor markers and various inflammation-related markers, their clinical 
      significance in differentiating benign and malignant pancreatic cystic neoplasms 
      (PCNs) remains to be clarified. The present study explored the value of serum 
      tumor markers and inflammation-related biomarkers in the differentiation of 
      pancreatic serous cystic neoplasms (SCNs) and pancreatic mucinous cystic 
      neoplasms (MCNs). A total of 79 patients with PCNs were included in this study, 
      including 35 patients with SCNs and 44 patients with MCNs. Comparison of baseline 
      data with preoperative results of serum tumor markers and associated inflammatory 
      markers revealed significant differences in carbohydrate antigen 199 (CA199) and 
      "lymphocyte x ALB" (LA) between the two groups (p = 0.0023, p = 0.0149, 
      respectively). Univariate and multivariate regression analyses showed that an 
      increase in CA199 and a decrease in LA were relevant risk factors for MCNs. 
      Finally, the receiver operating characteristic (ROC) curve was generated, and the 
      area under the ROC curve (AUC) was calculated to evaluate the prediction 
      efficiency of each indicator. The results showed that CA199 and LA had good 
      differential diagnostic efficacy for SCNs and MCNs. This is the first to report 
      to demonstrate that LA can be used for the differential diagnosis of SNCs and 
      MCNs.
CI  - Copyright (c) 2022 Wang, Chen, Shu, Liu, Liu, Zhu, Zhu and Xiong.
FAU - Wang, Huan
AU  - Wang H
AD  - The First Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Chen, Sihai
AU  - Chen S
AD  - The First Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Shu, Xu
AU  - Shu X
AD  - The First Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Liu, Zhijian
AU  - Liu Z
AD  - The First Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Liu, Pi
AU  - Liu P
AD  - The First Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Zhu, Yong
AU  - Zhu Y
AD  - The First Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Zhu, Yin
AU  - Zhu Y
AD  - The First Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Xiong, Huifang
AU  - Xiong H
AD  - The First Affiliated Hospital of Nanchang University, Nanchang, China.
LA  - eng
PT  - Journal Article
DEP - 20220225
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
CIN - Front Oncol. 2022 Jun 02;12:901010. PMID: 35720014
PMC - PMC8913928
OTO - NOTNLM
OT  - CA199
OT  - diagnose
OT  - mucinous cystic neoplasms
OT  - pancreatic cystic neoplasms
OT  - serous cystic neoplasms
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/15 06:00
MHDA- 2022/03/15 06:01
PMCR- 2022/01/01
CRDT- 2022/03/14 05:14
PHST- 2021/12/08 00:00 [received]
PHST- 2022/01/27 00:00 [accepted]
PHST- 2022/03/14 05:14 [entrez]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/03/15 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.831355 [doi]
PST - epublish
SO  - Front Oncol. 2022 Feb 25;12:831355. doi: 10.3389/fonc.2022.831355. eCollection 
      2022.